Aeluma, Inc. (ALMU) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2025. Aeluma, Inc. is a Delaware corporation developing novel optoelectronic and electronic devices using high-performance compound semiconductors on large-diameter substrates. The company operates a 9,000 sq. ft. R&D/manufacturing facility in Goleta, California, and targets markets including mobile, automotive, AI, defense, and quantum computing. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2025 | Nine Months Ended Mar 31, 2025 | As of Mar 31, 2025 |
|---|---|---|---|
| Revenue | $1,254,966 | $3,348,220 | - |
| Net Income (Loss) | $1,460,893 | $(2,163,550) | - |
| Operating Loss | $(831,470) | $(1,173,252) | - |
| Cash & Cash Equivalents | - | - | $3,865,659 |
| Certificates of Deposit | - | - | $12,000,000 |
| Total Current Assets | - | - | $17,225,995 |
| Total Current Liabilities | - | - | $525,843 |
| Working Capital | - | - | $16,700,152 |
| Stockholders' Equity | - | - | $17,997,095 |
Note: The Q3 2025 net income of $1.46M is primarily driven by a non-cash gain of $2.58M from the change in fair value of derivative liabilities upon conversion of notes.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 265% year-over-year for the nine months ended March 31, 2025 ($3.35M vs. $0.64M). This was driven by government contracts, which accounted for $3.15M of the nine-month total.
- Profitability Shift: The company reported a net loss of $3.57M for the nine months ended March 31, 2024, compared to a net loss of $2.16M for the same period in 2025. However, the Q3 2025 quarter turned profitable ($1.46M net income) due to the accounting treatment of convertible note conversions, whereas Q3 2024 was a loss of $0.96M.
- Liquidity Expansion: Total cash, cash equivalents, and certificates of deposit surged from $1.29M (June 30, 2024) to $15.87M (March 31, 2025). This increase is attributed to a public offering and convertible note issuances.
- Debt Elimination: Convertible notes totaling $3.145M principal were fully converted into common stock in March 2025, eliminating the associated debt obligations and derivative liabilities.
Guidance, Outlook, and Management Commentary
- Capital Raise: On March 26, 2025, Aeluma completed a public offering of 2.63M shares (including over-allotment) at $5.25 per share, generating net proceeds of $12.59M. Proceeds are designated for business development, scaling manufacturing, and general corporate purposes.
- Going Concern: Management states that the substantial doubt regarding the company's ability to continue as a going concern has been alleviated following the capital raise, providing sufficient liquidity for at least the next 12 months.
- Government Contracts: The company secured two significant government contracts totaling $11.87M during the nine-month period. Revenue from these firm-fixed-price contracts will be recognized over a 36-month period. As of March 31, 2025, remaining performance obligations totaled $9.41M.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing insufficient staffing resources in the finance department to support the complexity of financial reporting.
- Leadership: James Seo was appointed Interim Chief Financial Officer in March 2025.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue given that 94% of nine-month revenue ($3.15M) is derived from government contracts with long recognition periods (36 months).
- Non-Cash Income: Confirm that the Q3 2025 net income is largely non-cash, driven by the $2.58M gain on derivative liability conversion rather than operational profitability.
- Internal Control Deficiencies: Assess the timeline and plan for remediation of the ineffective disclosure controls and procedures.
- Cash Burn Rate: Monitor operating cash flow, which remained negative at $(1.08M) for the nine months ended March 31, 2025, despite the recent capital infusion.
- Dilution: Review the impact of the recent public offering and note conversions on share count, which increased from ~12.8M to ~15.8M shares outstanding.